24 jul: Bobler fra dybet fik hammerslag på rekordpriser ved nyligt afhold..
01 aug: Mercedes CLS Shooting Brake på vej til Danmark
30-07-2012 08:45:00

Reckitt Benckiser Warns on Mature Markets as Profit Rises

Relateret indhold

By Simon Zekaria

LONDON--Reckitt Benckiser PLC (RB.LN) Monday warned on a tough outlook for consumer spending in mature markets as it posted a slight rise in profit, helped by demand for household and medical products in emerging markets.

"While the consumer and competitive environment in Europe and North America remains challenging, we are doing the right things for the long term," said Chief Executive Rakesh Kapoor.

The U.K.-based maker of Air Wick air freshener, Dettol disinfectant and Neurofen pain relief tablets said net profit in the six months to June 30 rose 2.6% to GBP779 million ($1.22 billion) from GBP759 million a year earlier. Revenue in the period rose to GBP4.67 billion from GBP4.62 billion.

Second-quarter revenue fell 1.1% to GBP2.31 billion from GBP2.34 billion, missing market expectations from a company poll of GBP2.35 billion. However, like-for-like revenue rose 4%.

Unilever NV (UN) last week warned consumer companies are operating in a deteriorating global economy as it reported a small drop in net profit, while U.S.-based market leader Procter & Gamble Co. (PG) has issued two profit warnings this year, blaming weak demand in mature markets where spending is squeezed.

Rising middle-class populations with increased spending power in countries like Brazil, India and Indonesia are driving demand for high-margin health and hygiene goods. In contrast, Western economies, particularly in Europe, are seeing a cutback in consumer purchases amid weak economic conditions.

Earlier this year, Reckitt announced plans to merge its North American and European operations in a bid to focus investment and resources in emerging markets. Its goal is to generate half of its sales in developing economies, excluding food and pharmaceuticals, by 2016, up from just over 40% currently.

The move is aimed at reversing a recent slowdown in business. Last year saw the departure of CEO Bart Becht, the man credited with delivering consistent profit growth and more than quadrupling the company's share price since taking over in 1999. His replacement, Mr. Kapoor, is now tasked with guiding the company through an increasingly turbulent market.

Slough, England-based Reckitt Benckiser, which makes products as diverse as French's yellow mustard and Suboxone, a heroin addiction treatment, is aiming for comparable full-year revenue, excluding its pharmaceutical operations, to exceed forecast market growth of 1% to 2% by two percentage points, and to sustain this trajectory in the medium term. Excluding pharmaceuticals, it aims to maintain its operating margins.

It recommended an interim dividend of 56 pence a share, up 2% year-on-year.

Reckitt Benckiser shares closed Friday at 3542 pence, valuing the company at GBP25.61 billion, up 11% in the year to date.

Write to Simon Zekaria at simon.zekaria@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 30, 2012 02:45 ET (06:45 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Aktier/tendens: SAS klar med endelige regnskabstal før handelsstart

12-12-2017 08:15:47
Luftfartsselskabet SAS offentliggjorde forud for børsåbningen tirsdag sit endelige regnskab for det skæve regnskabsår 2016/17, og selskabet kan derfor løbe med en del af opmærksomheden ved handelsstart.Det danske aktiemarked kan gå endnu en grøn dag i møde på det ledende eliteindeks, hvis den amerikanske grønne bølge forplanter sig på de europæiske markeder.Mandag fik C20 Cap-indekset en positiv s..

Genmab-rival suser frem på børsen efter nyt kræftstudie

11-12-2017 15:04:38
Genmab kan om flere år møde øget konkurrence for sit største aktiv, kræftmidlet Darzalex, da det amerikanske biotekselskab Bluebird ifølge flere storbanker har et særdeles lovende middel under udvikling.Bluebird har fremlagt gode data for kræftmidlet CAR-T fra et fase 1-studie på konferencen ASH i USA, hvor Genmab også deltager med en præsentation.Goldman Sachs vurderer, at CAR-T ser ud til at vær..

Mærsk bliver overhalet af kinesisk konkurrent på robothavn

11-12-2017 12:24:01
Mærsks APM Terminals var først på banen med en fuldautomatiseret containerhavn i stor skala, men nu er selskabet ved at blive overhalet på størrelsen.I Yangshan nær Shanghai er det kinesiske havneselskab SIPG gået i gang med at teste verdens største automatiserede containerterminal.Yangshan-terminalen får en indledende kapacitet på 4 mio. tyvefodscontainere (TEU) om året, hvilket er godt halvanden..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Investeringsdirektør: Aktiepriserne bør få alarmlamperne til at blinke
2
Genmab-rival suser frem på børsen efter nyt kræftstudie
3
Genmab/Jefferies: Svært at se væsentlig konkurrencerisiko
4
TK Development tager markant nedskrivning og venter stort underskud
5
Genmab-aktien får kurstæsk efter forsigtig udmelding fra ledelsen

Relaterede aktiekurser

Unilever DR 48,77 0,2% Stigning i aktiekurs
Unilever PLC ORD 3 1/9P 4.199,50 0,3% Stigning i aktiekurs
Reckitt Benckiser Group .. 6.721,00 -0,2% Fald i aktiekurs
Procter & Gamble Company.. 90,23 0,0% Aktiekurs uændret
Unilever NV 57,43 0,0% Aktiekurs uændret
Unilever PLC 56,11 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
12. december 2017 11:10:52
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171124.1 - EUROWEB7 - 2017-12-12 11:10:52 - 2017-12-12 11:10:52 - 1 - Website: OKAY